Osaic Holdings
ADCT icon

Osaic Holdings’s ADC Therapeutics ADCT Stock Holding History

Osaic Holdings’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.29K Sell
4,009
-3,789
-49% -$11.1K ﹤0.01% 7011
2026
Q1 		$29.2K Sell
7,798
-1,526
-16% -$6.02K ﹤0.01% 5599
2025
Q4 		$32.9K Buy
9,324
+2,782
+43% +$11.3K ﹤0.01% 5529
2025
Q3 		$20.1K Sell
6,542
-2,959
-31% -$9.33K ﹤0.01% 5923
2025
Q2 		$25.5K Sell
9,501
-2,499
-21% -$5.26K ﹤0.01% 5532
2025
Q1 		$16.9K Buy
12,000
+128
+1% +$217 ﹤0.01% 5465
2024
Q4 		$23.6K Hold
11,872
– – ﹤0.01% 5237
2024
Q3 		$37.4K Buy
11,872
+1,000
+9% +$3.15K ﹤0.01% 4950
2024
Q2 		$34.4K Buy
10,872
+2,872
+36% +$11.4K ﹤0.01% 4968
2024
Q1 		$35.9K Sell
8,000
-6,000
-43% -$22.1K ﹤0.01% 4970
2023
Q4 		$23.2K Sell
14,000
-8,629
-38% -$7.96K ﹤0.01% 5419
2023
Q3 		$20.3K Buy
22,629
+11,465
+103% +$15.3K ﹤0.01% 5548
2023
Q2 		$24K Buy
11,164
+1,682
+18% +$3.78K ﹤0.01% 5445
2023
Q1 		$18.5K Buy
9,482
+2,898
+44% +$10.7K ﹤0.01% 5614
2022
Q4 		$25K Buy
6,584
+1,327
+25% +$5.31K ﹤0.01% 5414
2022
Q3 		$25K Sell
5,257
-226
-4% -$1.64K ﹤0.01% 5400
2022
Q2 		$44K Buy
5,483
+2,235
+69% +$21.1K ﹤0.01% 5050
2022
Q1 		$47K Buy
3,248
+3,011
+1,270% +$47.8K ﹤0.01% 5136
2021
Q4 		$5K Sell
237
-105
-31% -$2.53K ﹤0.01% 6602
2021
Q3 		$9K Sell
342
-50
-13% -$1.28K ﹤0.01% 6262
2021
Q2 		$9K Buy
392
+211
+117% +$4.9K ﹤0.01% 6127
2021
Q1 		$5K Hold
181
– – ﹤0.01% 6126
2020
Q4 		$6K Buy
181
+16
+10% +$524 ﹤0.01% 5693
2020
Q3 		$5K Sell
165
-14
-8% -$606 ﹤0.01% 5545
2020
Q2 		$8K Buy
+179
New +$6.79K ﹤0.01% 5266

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Osaic Holdings's ADCT Position: Q2 2026 in Review

Osaic Holdings reduced its ADC Therapeutics (ADCT) stake by 49% in Q2 2026, selling an estimated $11.1K and leaving 4,009 shares worth $4.29K. The position accounts for ﹤0.01% of the portfolio, ranked #7011.

Osaic Holdings first reported a position in ADCT in Q2 2020 and has held it in 25 quarters since. The position peaked at $47K in Q1 2022. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Osaic Holdings held 4,009 shares of ADC Therapeutics worth $4.29K as of Q2 2026.
  • Osaic Holdings sold 3,789 ADC Therapeutics shares in Q2 2026, an estimated $11.1K.
  • ADC Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #7011 holding.
  • Osaic Holdings first reported a position in ADC Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Osaic Holdings's ADC Therapeutics position peaked at $47K in Q1 2022.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.